Skip to main content
RCEL logo

Avita Medical Inc. (RCEL) Stock: Price, Forecast & Analyst Target

Avita Medical Inc. (RCEL) — MoonshotScore 20/100 (Weak band), calculated Nov 18, 2026. Price $15.99 (-4.99%), as of the Nov 19, 2026 trading session; market cap $507M.

Educational signal · not a buy or sell recommendation · How to read this

$15.99 −$0.84 (-4.99%) Market Cap $507M

Avita Medical Inc. · RCEL · NASDAQ

AVITA Medical Inc. is a commercial-stage regenerative tissue company focused on unmet medical needs in burn injuries, trauma, chronic wounds, and dermatological applications. Their lead product, the RECELL System, allows healthcare professionals to create Spray-On Skin cells from a patient's own skin for burn treatment.

Price as of Nov 19, 2026

Key Statistics

20 of 100

MoonshotScore v2 · Avita Medical (RCEL)

Weak
Business Quality Average (57)
Financial Safety Fragile (18)
Valuation Full (56)
Growth Durability Growing (61)
Momentum Surging (100)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A fragile balance sheet and a full valuation; the market is already moving on it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Average; Financial Safety: Fragile; Valuation: Full; Growth Durability: Growing; Momentum: Surging.

  • EPS beat 0 of the last 4 reports
  • Altman Z -8.68 · Piotroski F 4

Holding back: balance-sheet strain

Helping: positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for RCEL (57 recorded, newest six shown)
RecordedScoreBand
24Weak
25Weak
20Weak
20Weak
20Weak
20Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$15.99
Change on the day-4.99%
52-week range$3.22 – $18.43
Market capitalisation$507M—
Shares traded on the day362.5K

Price & events

Other perspectives

Council score for Avita Medical (RCEL): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Neutral
Financial Safety Negative
Valuation Neutral
Growth Durability Moderate
Momentum Strong

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Favorable read

Read on: Nov 19, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Gross Margin Strong

Read on: Nov 19, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Three of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens, Simons-style lens and Moon AI lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Avita Medical (RCEL), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Avita Medical Inc. (RCEL) is listed on NASDAQ. It employs 226 people and is led by Cary G. Vance. The market values it at $507M.

2 · Latest results

What do the latest results show for Avita Medical (RCEL)?

Short answer · as of

Against analyst estimates the company has EPS beat 0 of the last 4 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$17M-$13M-$0.46 (diluted)
Q4 FY2025$18M-$12M-$0.38 (diluted)
Q1 FY2026$19M-$11M-$0.35 (diluted)
Q2 FY2026$22M-$8M-$0.25 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Avita Medical (RCEL)?

Short answer

The MoonshotScore pillars rate positive momentum as strengths. What is holding it back is balance-sheet strain. The distress and quality screens read Altman Z -8.68 · Piotroski F 4. Trailing ratios: ROA -32.5% · current ratio 1.20.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -8.68 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
4 · What to check next?

What should you watch next at Avita Medical (RCEL)?

Short answer · as of

Current published price targets run low $11.00 · high $20.00 · consensus $14.33 · median $12.00 against a quoted price of $15.99 (as of Nov 19, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Avita Medical compare with its peers?

Short answer

Avita Medical's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Delcath Systems, Inc. (DCTH) Same industry, near in market value$19.24 Nov 19, 2026$669M94 5-pillar Nov 18, 2026
InMode Ltd. (INMD) Same industry, near in market value$12.88 Nov 18, 2026$741M92 5-pillar Nov 18, 2026
Tactile Systems Technology, Inc. (TCMD) Same industry, near in market value$26.42 Nov 18, 2026$592M90 5-pillar Nov 18, 2026
Viemed Healthcare, Inc. (VMD) Same industry, near in market value$8.61 Nov 19, 2026$326M88 5-pillar Nov 18, 2026
BrainsWay Ltd. (BWAY) Same industry, near in market value$8.98 Nov 18, 2026$361M87 5-pillar Nov 18, 2026
Bioventus Inc. (BVS) Same industry, near in market value$10.62 Nov 18, 2026$727M79 5-pillar Nov 18, 2026
Varex Imaging Corporation (VREX) Same industry, near in market value$18.15 Nov 18, 2026$771M62 5-pillar Nov 18, 2026
OrthoPediatrics Corp. (KIDS) Same industry, near in market value$32.51 Nov 19, 2026$849M37 5-pillar Nov 18, 2026
Orthofix Medical Inc. (OFIX) Same industry, near in market value$6.34 Nov 19, 2026$258M36 5-pillar Nov 18, 2026
908 Devices Inc. (MASS) Same industry, near in market value$9.52 Nov 18, 2026$396M35 5-pillar Nov 18, 2026
Sight Sciences, Inc. (SGHT) Same industry, near in market value$10.62 Nov 19, 2026$590M34 5-pillar Nov 18, 2026
Artivion Inc. (AORT) Same industry, near in market value$18.54 Nov 18, 2026$905M34 5-pillar Nov 18, 2026
Avita Medical (RCEL) — this page$15.99$507M20

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$11.00 – $20.00
Consensus target
$14.33
Median target
$12.00

Consensus record · Captured .

Measured against a quoted price of $15.99 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Jun 12, 2026

Transactions
9
Identified insiders
3
Purchases
6
Sales
0
Other transactions
3

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held RCEL in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported RCEL in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Avita Medical (RCEL)?

Read these with our analysis →

Investor Questions: RCEL Stock

These answers are editorial: 1 of these 9 answers is drawn from the RCEL research dossier (written May 4, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for RCEL?

RCEL carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is RCEL a good stock to buy?

Stock Expert AI does not rate RCEL buy, sell or hold. Avita Medical Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the RCEL stock price today?

The last price recorded for Avita Medical Inc. (RCEL), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the RCEL price target?

The analyst consensus price target for Avita Medical Inc. (RCEL), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What do analysts say about RCEL stock?

Analyst coverage of AVITA Medical (RCEL) is limited, reflecting its small-cap status and focus on a niche market. Current sentiment is cautiously optimistic, with analysts noting the potential of the RECELL System and its expansion into new indications.

What are the key factors to evaluate for RCEL?

Avita Medical Inc. (RCEL) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. RECELL System is AVITA Medical's lead product, offering a novel approach to burn treatment using Spray-On Skin cells derived from the patient's own skin. Not financial advice.

How frequently does RCEL data refresh on this page?

RCEL's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven RCEL's recent stock price performance?

Avita Medical Inc. (RCEL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary RECELL System technology. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider RCEL overvalued or undervalued right now?

Avita Medical Inc. (RCEL) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 4, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 17 figures on this page — 10 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.